Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306161 | 0.94 | POLB (0.81) | POLBKMT2AMEN1MAPK1HTT | |
| Iodide SCHEMBL22235392 | 0.93 | POLB (0.78) | POLBKMT2AMEN1MAPK1HTT | |
| SCHEMBL4236814 | 0.89 | POLB (0.73) | POLBKMT2AMEN1MAPK1GAA | |
| SCHEMBL27396578 | 0.86 | POLB (0.79) | POLBKMT2AMEN1MAPK1GAA | |
| SCHEMBL31504041 | 0.86 | POLB (0.69) | POLBKMT2AMEN1MAPK1MAPT | |
| Sulfamide SCHEMBL27805329 | 0.86 | POLB (0.79) | POLBKMT2AMEN1MAPK1GAA | |
| 4-Nitrobenzoic Acid SCHEMBL27562391 | 0.86 | TDP1 (0.70) | POLBKMT2AMEN1MAPK1HTT | |
| SCHEMBL12973292 | 0.85 | POLB (0.68) | POLBKMT2AMEN1MAPK1MAPT | |
| SCHEMBL7450958 | 0.85 | POLB (0.77) | POLBKMT2AMEN1MAPK1GAA | |
| SCHEMBL14659792 | 0.85 | POLB (0.68) | POLBKMT2AMEN1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264043-B1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7989601-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2264043-A1 | Heterobifunctional pan-selectin inhibitors | GlycoMimetics, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100204170-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-7728117-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | GLYCOMIMETICS, INC (US) | 2009-02-05 | — | — | US | disclosed |
| US-7361644-B2 | Specific antagonist for both E- and P-selectins | GLYCOMIMETICS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | SELE, SELL, BSG | POLB 4590/4885KMT2A 2610/4885MEN1 3603/4885 |
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | POLB 4205/4885KMT2A 2335/4885MEN1 3689/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | POLB 4205/4885KMT2A 2335/4885MEN1 3689/4885 |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | BSG, SELE, SELL | POLB 4325/4885KMT2A 3600/4885MEN1 2258/4885 |
| US-20100204170-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | POLB 4205/4885KMT2A 2335/4885MEN1 3689/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | POLB 4205/4885KMT2A 2335/4885MEN1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.